03263nas a2200385   4500008004100000022004200041245016500083210006900248250001000317260000800327300001200335490000700347520190800354653002902262653001802291653001002309653002502319653004302344653002702387653001102414653001902425653007402444653004602518653005802564653001102622653000902633653001602642653005502658653005302713100001702766700001702783700001602800700001302816856004802829       2006                        eng d  a1744-9979 (Print) 1744-9979 (Linking)00arHuG-CSF increases the platelet-neutrophil complex formation and neutrophil adhesion molecule expression in volunteer granulocyte and stem cell apheresis donors0 arHuGCSF increases the plateletneutrophil complex formation and n  a38848  cApr  a180 - 60 v103 aSeveral reports have shown that granulocyte colony-stimulating factor (G-CSF) administration induces a transient, mild hypercoagulable state, which might predispose certain donors to thrombotic complications. In the present study, changes in the expression of neutrophil adhesion molecules (CD11b/CD18, CD62L) and platelet-neutrophil complex formation following rHuG-CSF administration were investigated in normal granulocyte and stem cell donors. For granulocyte apheresis (N = 10), rHuG-CSF (5 microg/kg) was given subcutaneously every 12 h three times and apheresis was carried out two hours after the last dose. For stem cell apheresis (N = 8), rHuG-CSF (10 microg/kg/day) was given subcutaneously for 5 days and apheresis was carried out when peripheral CD34+ cell counts exceeded 20 cell/microL. Expression of neutrophil adhesion molecules (CD11b/CD18, CD62L) and platelet-neutrophil complex formation following rHuG-CSF administration were investigated in donors by a flow cytometric method. A significant increase in neutrophil counts (P < 0.001), and decreases in platelet counts (P < 0.01) and hemoglobin levels (P < 0.01) occurred following G-CSF administration. The expression of CD11b/CD18 significantly increased (P < 0.001) over pretreatment values with G-CSF administration and returned to baseline 1 week after stopping the drug. In contrast, CD62L expression was decreased (P < 0.01) with G-CSF and returned to normal after cessation of the drug. rHuG-CSF caused more than a two-fold increase (from 0.3 to 7.0 x 10(9)/L) in circulating platelet-neutrophil complexes (P < 0.01), which returned to normal after 1 week. Although clinical significance of these laboratory changes is not clear, the occurrence of neutrophil activation and increased platelet-neutrophil complex formation might predispose certain donors or patients to thrombotic complications following G-CSF administration.10a*Blood Component Removal10a*Blood Donors10aAdult10aAnalysis of Variance10aCell Adhesion Molecules / drug effects10adosage / *pharmacology10aFemale10aFlow Cytometry10aGranulocyte Colony Stimulating Factor, Recombinant / administration &10aGranulocytes / drug effects / *physiology10aHematopoietic Stem Cells / drug effects / *physiology10aHumans10aMale10aMiddle Aged10aNeutrophil Activation / drug effects / *physiology10aPlatelet Activation / drug effects / *physiology1 aKaradogan, C1 aKaradogan, I1 aBilgin, A U1 aUndar, L  uhttps://www.notifylibrary.org/reference/757